Late-stage catalyst intelligence for psychedelic trials
A research desk for the trials most likely to matter next. Blossom ranks late-stage studies on a transparent registry checklist, and shows you the inputs behind every position so you can judge the reasoning rather than take it on trust.
How the ranking works
Each trial scores against six registry criteria: readout timing, enrolment, sponsor track record, regulatory or efficacy signal, whether results are attached, and phase. Open any row to see which criteria it meets and what the score would be if one changed. It is a ranking heuristic, not a probability.
Coverage at a glance
Covered Catalysts
73
Grouped programmes + standalone trials
Near Readout (<=24m)
45
Expected completion window
Phase 3 Share
40%
Coverage composition
Average Catalyst Score
57.7
Weighted registry checklist, 0-100
Registry Moves (7d)
73
Trials whose registry record changed
Showing 73 high-signal catalysts
Late-stage programmes and large Phase 2 trials with a named sponsor and a readout ahead.
Some covered catalysts carry compound- or programme-level FDA Breakthrough Therapy Designation. The badge is a context marker, not an approval forecast; the ranking still comes from phase, timing, evidence, and sponsor execution.
7
BTD catalysts
3
Grouped programmes
Phase 3 Catalyst Screener
Highest-priority late-stage programmes, ranked by near-term catalyst impact.
The default view covers grouped pivotal programmes, active Phase 3 studies, and Phase 2 trials with meaningful scale and a linked developer. Switching to the full Phase 2/3 set adds smaller and investigator-led work.
Terminated and withdrawn studies stay out of both views, as do completed trials whose results have already been published: once the readout is in the literature there is no catalyst left to rank. Recently completed trials with no published results remain, because their disclosure is still ahead.